Evidence map›Paper›PMID 25076860›Full record

ArticleInternational journal of biological sciences2014

Establishment and characterization of a highly tumorigenic African American prostate cancer cell line, E006AA-hT.

Shahriar Koochekpour, Stacey S Willard, Mojgan Shourideh, Shafat Ali, Chunhong Liu, Gissou Azabdaftari, Mohammad Saleem, Kristopher Attwood

Abstract read
In one paragraph

Article in International journal of biological sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Article
  3. Genetic Ancestry Analysis Reveals Misclassification of Commonly Used Cancer Cell Lines.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shahriar Koochekpour1. Department of Cancer Genetics, Center for Genetics and Pharmacology, Roswell Park Cancer Institute, New York, United States of America; ; 2. Department of Urology, Center for Genetics and Pharmacology, Roswell Park Cancer Institute, New York, United States of America;
Stacey S Willard1. Department of Cancer Genetics, Center for Genetics and Pharmacology, Roswell Park Cancer Institute, New York, United States of America;
Mojgan Shourideh1. Department of Cancer Genetics, Center for Genetics and Pharmacology, Roswell Park Cancer Institute, New York, United States of America;
Shafat Ali1. Department of Cancer Genetics, Center for Genetics and Pharmacology, Roswell Park Cancer Institute, New York, United States of America;
Chunhong Liu1. Department of Cancer Genetics, Center for Genetics and Pharmacology, Roswell Park Cancer Institute, New York, United States of America;
Gissou Azabdaftari3. Department of Pathology, Center for Genetics and Pharmacology, Roswell Park Cancer Institute, New York, United States of America;
Mohammad Saleem4. Molecular Chemoprevention and Therapeutics, The Hormel Institute, University of Minnesota, Austin, Minnesota, United States of America;
Kristopher Attwood5. Department of Biostatistics, University of Buffalo, New York, United States of America.

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African AmericansR01MD005824 · NIMHD · ROSWELL PARK CANCER INSTITUTE CORP · PI KOOCHEKPOUR, SHAHRIAR · 2010 to 2013
$1.5M
Metabotropic Glutamate Receptor 1 in African American Prostate CancerR21CA183892 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI KOOCHEKPOUR, SHAHRIAR · 2014 to 2015
$406k
NCI NIH HHS P30 CA016056NCI NIH HHS R21 CA183892NCI NIH HHS R21CA183892NIMHD NIH HHS R01 MD005824NIMHD NIH HHS R01MD005824
6 · The paper itself

Abstract

Genuine racial differences in prostate cancer (PCa) biology have been considered among the potential reasons to explain PCa disparities. There is no animal model to represent all aspects of human PCa and, more specifically, to be used for PCa disparity research. The lack of a spontaneously transformed in vitro cell-based model system has been a significant impediment to investigating and understanding potential molecular mechanisms, and the hormonal, genetic, and epigenetic factors underlying the biological and clinical aggressiveness of PCa in African American (AA) men. In this study, we established and characterized the E006AA-hT cell line as a highly tumorigenic subline of the previously characterized primary AA-PCa cell line, E006AA. Extensive characterization of the E006AA-hT cell line was accomplished using cytodifferentiation and prostate-specific markers, spectral karyotyping, cell line authentication assays, cell proliferation and migration assays, and in vitro tumorigenesis assays. Spectral karyotyping of E006AA-hT showed a hypertriploid chromosome complement and shared cytogenetic changes similar to its parental cells such as diploid X, absence of Y-chromosomes, numerical gains in chromosomes 5,6,8,10,17,20,21, and marker chromosomes of unknown origin. In addition, E006AA-hT also presented numerous clonal and structural aberrations such as insertion, deletion, duplication, and translocations in chromosomes 1-5, 8, 9, 11, 13, 14, 17, and 18. The E006AA-hT cell line was shown to be highly tumorigenic and produced tumors at an accelerated growth rate in both athymic nude and triple-deficient SCID mice. Silencing the mutated androgen receptor (AR-599 Ser>Gly) did not affect proliferation (loss-of-function), but decreased migration (gain-of-function) in E006AA-hT and its parental cell type. These data support that AR-point mutations may lead simultaneously to different "loss-of-function" and "gain-of-function" phenotypes in PCa cells. E006AA-Par and its subline as the only available spontaneously transformed low- and highly-tumorigenic primary AA-PCa cell lines could be used for basic and translational research aimed in supporting prostate cancer disparity research.

Indexed as

Black or African AmericanCell Line, TumorHumansMaleProstatic NeoplasmsReceptors, AndrogenReceptors, AndrogenAfrican AmericanAndrogen ReceptorE006AAProstate Cancertumorigenic.

Identifiers

PMID25076860
PMCPMC4115195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.